Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15031600,"peak plasma 1,25-D(3) concentrations (Cp(max))","After 0.125 and 0.5 microg dosing, peak plasma 1,25-D(3) concentrations (Cp(max)) were 12.0 ng/ml (CI 95%, 10.8-12.6) and 41.6 ng/ml (CI 95%, 40.8-53.6), respectively.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[ng] / [ml],12.0,664,DB00136,Calcitriol
,15031600,"peak plasma 1,25-D(3) concentrations (Cp(max))","After 0.125 and 0.5 microg dosing, peak plasma 1,25-D(3) concentrations (Cp(max)) were 12.0 ng/ml (CI 95%, 10.8-12.6) and 41.6 ng/ml (CI 95%, 40.8-53.6), respectively.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[ng] / [ml],41.6,665,DB00136,Calcitriol
,15031600,areas under the curve (AUC(0->24 h)),"The corresponding areas under the curve (AUC(0->24 h)) were 47.0 (CI 95%, 43.2-51.1) and 128.0 (CI 95%, 127.0-130.0) ng.h/ml.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[h·ng] / [ml],47.0,666,DB00136,Calcitriol
,15031600,areas under the curve (AUC(0->24 h)),"The corresponding areas under the curve (AUC(0->24 h)) were 47.0 (CI 95%, 43.2-51.1) and 128.0 (CI 95%, 127.0-130.0) ng.h/ml.","Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031600/),[h·ng] / [ml],128.0,667,DB00136,Calcitriol
,17317832,C(max),Mean (+/-SD) serum calcitriol C(max) at the MTD was 6.68 +/- 1.42 ng/mL.,A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17317832/),[ng] / [ml],6.68,5382,DB00136,Calcitriol
,3631255,metabolic clearance rate,"By use of this technique we found that the metabolic clearance rate of 1,25-dihydroxyvitamin D3 in dogs was 6.3 +/- 1.2 ml/min (mean +/- SD); the production rate of the hormone was 0.40 +/- 0.25 microgram/day (20.4 +/- 14.4 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ml] / [min],6.3,5713,DB00136,Calcitriol
,3631255,production rate,"By use of this technique we found that the metabolic clearance rate of 1,25-dihydroxyvitamin D3 in dogs was 6.3 +/- 1.2 ml/min (mean +/- SD); the production rate of the hormone was 0.40 +/- 0.25 microgram/day (20.4 +/- 14.4 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[μg] / [d],0.40,5714,DB00136,Calcitriol
,3631255,production rate,"By use of this technique we found that the metabolic clearance rate of 1,25-dihydroxyvitamin D3 in dogs was 6.3 +/- 1.2 ml/min (mean +/- SD); the production rate of the hormone was 0.40 +/- 0.25 microgram/day (20.4 +/- 14.4 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ng] / [d·kg],20.4,5715,DB00136,Calcitriol
,3631255,metabolic clearance rate,"In eight normal women, aged 28-51 yr, the metabolic clearance rate for 1,25-dihydroxyvitamin D3 was 25.9 +/- 4.7 ml/min; the production rate was 1.38 +/- 0.45 microgram/day (20.7 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ml] / [min],25.9,5716,DB00136,Calcitriol
,3631255,production rate,"In eight normal women, aged 28-51 yr, the metabolic clearance rate for 1,25-dihydroxyvitamin D3 was 25.9 +/- 4.7 ml/min; the production rate was 1.38 +/- 0.45 microgram/day (20.7 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[μg] / [d],1.38,5717,DB00136,Calcitriol
,3631255,production rate,"In eight normal women, aged 28-51 yr, the metabolic clearance rate for 1,25-dihydroxyvitamin D3 was 25.9 +/- 4.7 ml/min; the production rate was 1.38 +/- 0.45 microgram/day (20.7 ng . kg-1 . day-1).","A primed-infusion technique for rapid estimation of the metabolic clearance rate of 1,25(OH)2D3. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3631255/),[ng] / [d·kg],20.7,5718,DB00136,Calcitriol
,16411524,maximum serum concentration,"The maximum serum concentration after IP administration of 10 microg OCT was 750 pg/mL after 5 minutes, and remained at 500 pg/mL at 60 minutes.",Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411524/),[pg] / [ml],750,9093,DB00136,Calcitriol
,16411524,maximum serum concentration,"The maximum serum concentration after IP administration of 10 microg OCT was 750 pg/mL after 5 minutes, and remained at 500 pg/mL at 60 minutes.",Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411524/),[pg] / [ml],500,9094,DB00136,Calcitriol
,24854296,half-life,These results coupled with a pharmacokinetic half-life of ~24 h suggest that 2MD given either daily or at the time of dialysis may be a superior therapy for secondary hyperparathyroidism in chronic renal failure patients.,"Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24854296/),h,24,12317,DB00136,Calcitriol
,21124302,half-life,There was a single exponential decay with a half-life of 33 min.,Treatment with pyrophosphate inhibits uremic vascular calcification. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21124302/),min,33,23024,DB00136,Calcitriol
,28905271,half-life,"After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively).","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,55.8,28814,DB00136,Calcitriol
,28905271,half-life,"After the first and final dose, the half-life of DP001 was similar (55.8 ± 13.0 and 50.8 ± 8.2 h, respectively).","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,50.8,28815,DB00136,Calcitriol
,28905271,time to maximum plasma concentration,"At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),h,4.0,28816,DB00136,Calcitriol
,28905271,concentration maximum,"At 4 weeks, the time to maximum plasma concentration was 4.0 ± 0.8 h, with a concentration maximum of 3.4 ± 0.3 pg/mL.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[pg] / [ml],3.4,28817,DB00136,Calcitriol
,28905271,area under the curve (0 to infinity),"The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[h·pg] / [ml],204.3,28818,DB00136,Calcitriol
,28905271,apparent volume of distribution,"The area under the curve (0 to infinity) after the final dose was 204.3 ± 23.9 pg h/mL, and apparent volume of distribution was 2.03 ± 0.22 L/kg.","Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D3) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28905271/),[l] / [kg],2.03,28819,DB00136,Calcitriol
,8494933,peak levels,"Serum calcitriol levels reached peak levels of 60 and 70 pg/mL at 1 and 2 hours after administration, respectively.",The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494933/),[pg] / [ml],60,31616,DB00136,Calcitriol
,8494933,peak levels,"Serum calcitriol levels reached peak levels of 60 and 70 pg/mL at 1 and 2 hours after administration, respectively.",The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494933/),[pg] / [ml],70,31617,DB00136,Calcitriol
,8494933,area under the curve (AUC),The mean value of the area under the curve (AUC) was 809 +/- 226 pg/mL/hour.,The pharmacokinetics of a single dose of calcitriol administered subcutaneously in continuous ambulatory peritoneal dialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8494933/),[pg] / [h·ml],809,31618,DB00136,Calcitriol
,16759888,bioavailability,"The bioavailability of 1,25(OH)(2)D(3) administered IVAG at 1.0microg/kg BW was approximately 93%.","Dose response to vaginal administration of 1,25-dihydroxyvitamin D3 to cows. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16759888/),%,93,32669,DB00136,Calcitriol
,8704116,AUC0-0.5,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,105,33067,DB00136,Calcitriol
,8704116,AUC0-0.5,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,9,33068,DB00136,Calcitriol
,8704116,AUC0.5-1,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,68,33069,DB00136,Calcitriol
,8704116,AUC0.5-1,"The AUC0-0.5 (105 +/- 12, i.v.; 9 +/- 4, oral) and AUC0.5-1 (68 +/- 6, i.v.; 30 +/- 7, oral) were higher with i.v. (P < 0.05), but cumulative AUC0-48 did not differ.",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),,30,33070,DB00136,Calcitriol
,8704116,t1/2,Individual t1/2 values ranged from 10 to 129 h for PK1 and from 10 to 50 h for PK2.,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,10 to 129,33071,DB00136,Calcitriol
,8704116,t1/2,Individual t1/2 values ranged from 10 to 129 h for PK1 and from 10 to 50 h for PK2.,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,10 to 50,33072,DB00136,Calcitriol
,8704116,t1/2,The t1/2 for oral calcitriol was 38 +/- 14 h for PK1 and 30 +/- 4 h for PK2 (not significant (NS)).,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,38,33073,DB00136,Calcitriol
,8704116,t1/2,The t1/2 for oral calcitriol was 38 +/- 14 h for PK1 and 30 +/- 4 h for PK2 (not significant (NS)).,Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,30,33074,DB00136,Calcitriol
,8704116,t1/2,"The t1/2 for i.v. calcitriol was 26 +/- 5 h for PK1 and 19 +/- 3 h for PK2 (NS, PK1 versus PK2 and oral versus i.v.).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,26,33075,DB00136,Calcitriol
,8704116,t1/2,"The t1/2 for i.v. calcitriol was 26 +/- 5 h for PK1 and 19 +/- 3 h for PK2 (NS, PK1 versus PK2 and oral versus i.v.).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,19,33076,DB00136,Calcitriol
,8704116,t1/2,"When the PK1 oral and i.v. data were combined, the mean t1/2 was 32 +/- 7 h whereas the t1/2 for PK2 (oral and i.v.) was 22 +/- 3 h (P < 0.05).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,32,33077,DB00136,Calcitriol
,8704116,t1/2,"When the PK1 oral and i.v. data were combined, the mean t1/2 was 32 +/- 7 h whereas the t1/2 for PK2 (oral and i.v.) was 22 +/- 3 h (P < 0.05).",Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704116/),h,22,33078,DB00136,Calcitriol
,2996826,metabolic clearance rate,"The metabolic clearance rate of 1,25-dihydroxyvitamin D3 was the same in both normal heterozygous (0.90 +/- 0.02) and hypocalcaemic, homozygous piglets (0.90 +/- 0.01 ml-1 min-1 kg-1 metabolic body size).","Effect of 1,25-dihydroxyvitamin D deficiency on the metabolic clearance rate of 1,25-dihydroxyvitamin D3: studies using pigs with vitamin D-dependent rickets type 1. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2996826/),1/[kg·min·ml],0.90,33574,DB00136,Calcitriol
,2996826,metabolic clearance rate,"The metabolic clearance rate of 1,25-dihydroxyvitamin D3 was the same in both normal heterozygous (0.90 +/- 0.02) and hypocalcaemic, homozygous piglets (0.90 +/- 0.01 ml-1 min-1 kg-1 metabolic body size).","Effect of 1,25-dihydroxyvitamin D deficiency on the metabolic clearance rate of 1,25-dihydroxyvitamin D3: studies using pigs with vitamin D-dependent rickets type 1. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2996826/),1/[kg·min·ml],0.90,33575,DB00136,Calcitriol
,2058667,steady-state levels,Conscious adult (7-mo-old) and aged (25-mo-old) male Sprague-Dawley rats were infused for 2 h with rat PTH-(1-34) to achieve steady-state levels in plasma (110-120 pg/ml).,Heterogeneous response to PTH in aging rats: evidence for skeletal PTH resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058667/),[pg] / [ml],110-120,34018,DB00136,Calcitriol
,2058667,metabolic clearance rate,"The metabolic clearance rate of irPTH was rapid and not different in adult and aged rats (99 +/- 8 vs. 111 +/- 7 ml.min-1.kg-1, respectively).",Heterogeneous response to PTH in aging rats: evidence for skeletal PTH resistance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058667/),[ml] / [kg·min],99,34019,DB00136,Calcitriol
,2058667,metabolic clearance rate,"The metabolic clearance rate of irPTH was rapid and not different in adult and aged rats (99 +/- 8 vs. 111 +/- 7 ml.min-1.kg-1, respectively).",Heterogeneous response to PTH in aging rats: evidence for skeletal PTH resistance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058667/),[ml] / [kg·min],111,34020,DB00136,Calcitriol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.7,34760,DB00136,Calcitriol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.8,34761,DB00136,Calcitriol
,2709678,Basal MCR,"Basal MCR in uremic dogs, either with moderate or with severe renal failure, did not differ significantly from normals (6.7 +/- 0.7, 6.8 +/- 0.4 and 6.8 +/- 0.3 ml/min, respectively).",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),[ml] / [min],6.8,34762,DB00136,Calcitriol
,2709678,production,"25(OH)D treatment did not affect production rates in normal dogs and in animals with moderate renal failure (with normal basal values of 1,25(OH)2D), but significantly increased 1,25(OH)2D production from 0.13 +/- 0.01 to 0.25 +/- 0.04 micrograms/day (P less than 0.05) in dogs with severe renal insufficiency.",Metabolic clearance rate and production rate of calcitriol in uremia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2709678/),,0,34763,DB00136,Calcitriol
,21477267,T(max),The median for digoxin T(max) was 0.75 h before and after vitamin D3 ingestion.,Effect of vitamin D3 supplementation on the pharmacokinetics of digoxin--a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477267/),h,0.75,41061,DB00136,Calcitriol
,9673570,rate,Basal plasma Pi concentrations of 1.6 +/- 0.3 mM (NaCl infusion) were associated with a renal resorption of the filtered Pi by 98.5-99.3% and Pi was excreted in the urine at a rate of 1.2-2.8 mumol/min.,Renal phosphate excretion in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673570/),[μM] / [min],1.2-2.8,41522,DB00136,Calcitriol
,9673570,maximum level,In relation to the enhanced Pi concentrations in plasma the salivary Pi concentrations increased simultaneously and reached a maximum level of about 66.3 mM at plasma levels between 4-6 mM.,Renal phosphate excretion in goats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673570/),mM,66.3,41523,DB00136,Calcitriol
,20921291,area under the curve over 48 h (AUC(0-48)),"Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48 h (AUC(0-48)) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respectively; P = 0.171].",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],429,46285,DB00136,Calcitriol
,20921291,area under the curve over 48 h (AUC(0-48)),"Co-administration of lanthanum carbonate with calcitriol had no significant effect on area under the curve over 48 h (AUC(0-48)) for serum exogenous calcitriol [least-squares (LS) mean, calcitriol with lanthanum carbonate vs calcitriol alone: 429 pg h/mL vs 318 pg h/mL, respectively; P = 0.171].",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],318,46286,DB00136,Calcitriol
,20921291,AUC(0-48),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],137,46287,DB00136,Calcitriol
,20921291,AUC(0-48),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[h·pg] / [ml],318,46288,DB00136,Calcitriol
,20921291,C(max),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[pg] / [ml],40.1,46289,DB00136,Calcitriol
,20921291,C(max),"In contrast, co-administration with sevelamer was associated with a significant reduction in bioavailability parameters for calcitriol (calcitriol with sevelamer carbonate vs calcitriol alone, LS mean AUC(0-48): 137 pg h/mL vs 318 pg h/mL, respectively; P = 0.024; LS mean C(max): 40.1 pg/mL vs 49.7 pg/mL, respectively; P < 0.001).",The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20921291/),[pg] / [ml],49.7,46290,DB00136,Calcitriol
,7923966,Cmax,"The highest measured concentrations of 1,25(OH)2D3 were found at 1.5 h for both oral and IP treatments (mean Cmax [SD]: oral 116 [23] pmol/l, IP 121 [24] pmol/l, p > 0.05).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [l],116,47523,DB00136,Calcitriol
,7923966,Cmax,"The highest measured concentrations of 1,25(OH)2D3 were found at 1.5 h for both oral and IP treatments (mean Cmax [SD]: oral 116 [23] pmol/l, IP 121 [24] pmol/l, p > 0.05).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [l],121,47524,DB00136,Calcitriol
,7923966,AUC's,"The AUC's for oral and IP therapy were similar (1701 [276] and 1645 [301] pmol/h/l, respectively).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [h·l],1701,47525,DB00136,Calcitriol
,7923966,AUC's,"The AUC's for oral and IP therapy were similar (1701 [276] and 1645 [301] pmol/h/l, respectively).","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),[pM] / [h·l],1645,47526,DB00136,Calcitriol
,7923966,serum half life,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,27.4,47527,DB00136,Calcitriol
,7923966,serum half life,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,19.2,47528,DB00136,Calcitriol
,7923966,total body clearance,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,15.3,47529,DB00136,Calcitriol
,7923966,total body clearance,"In the paired pharmacokinetic studies no significant differences were found between oral and IP treatments for the serum half life (27.4 [11.6] h and 19.2 [8.1] h, respectively) and total body clearance (15.3 [2.1] h and 18.4 [3.3] h, respectively) of 1,25(OH)2D3.","Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923966/),h,18.4,47530,DB00136,Calcitriol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],25.8,51628,DB00136,Calcitriol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],20.2,51629,DB00136,Calcitriol
,2405696,Clearance rates,"Clearance rates of 1,25(OH)2D of 25.8 +/- 1.31 microliters/min in pregnant rats and 20.2 20.2 +/- 1.38 microliters/min in nonpregnant aged-matched rats were not significantly different.","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[μl] / [min],20.2,51630,DB00136,Calcitriol
,2405696,apparent volume of distribution,"Similarly, the apparent volume of distribution of 1,25(OH)2D in the pregnant rats (15 +/- 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 +/- 2.1 ml).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),ml,15,51631,DB00136,Calcitriol
,2405696,apparent volume of distribution,"Similarly, the apparent volume of distribution of 1,25(OH)2D in the pregnant rats (15 +/- 1.0 ml) was not significantly different from that in the nonpregnant control animals (18 +/- 2.1 ml).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),ml,18,51632,DB00136,Calcitriol
,2405696,Production rates,"Production rates of.1,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[pg] / [min],2.83,51633,DB00136,Calcitriol
,2405696,Production rates,"Production rates of.1,25(OH)2D were elevated in the pregnant rats (2.83 pg/min) compared with the nonpregnant controls (1.55 pg/min).","Pregnancy does not alter the metabolic clearance of 1,25-dihydroxyvitamin D in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2405696/),[pg] / [min],1.55,51634,DB00136,Calcitriol
,20306264,MTD,"In an earlier canine study, the MTD of intravenous (i.v.) calcitriol was 3.75 μg/kg, but polysorbate-associated hypersensitivity reactions were common.","Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306264/),[μg] / [kg],3.75,52288,DB00136,Calcitriol
,20306264,oral bioavailability,"Calcitriol oral bioavailability was highly variable among dogs (mean ± SEM, 71 ± 12.6%).","Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306264/),%,71,52289,DB00136,Calcitriol
,8368291,metabolic clearance rate,"Diabetic rats had an increased metabolic clearance rate of 1,25-(OH)2D3 (0.38 +/- 0.015 vs. 0.24 +/- 0.007 ml.min-1.kg-1), with no further increase in 1,25(OH)2D3-infused diabetic rats; their relative production rate of 1,25(OH)2D3 was unchanged.","Increased clearance of 1,25(OH)2D3 and tissue-specific responsiveness to 1,25(OH)2D3 in diabetic rats. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368291/),[ml] / [kg·min],0.38,53280,DB00136,Calcitriol
,8368291,metabolic clearance rate,"Diabetic rats had an increased metabolic clearance rate of 1,25-(OH)2D3 (0.38 +/- 0.015 vs. 0.24 +/- 0.007 ml.min-1.kg-1), with no further increase in 1,25(OH)2D3-infused diabetic rats; their relative production rate of 1,25(OH)2D3 was unchanged.","Increased clearance of 1,25(OH)2D3 and tissue-specific responsiveness to 1,25(OH)2D3 in diabetic rats. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368291/),[ml] / [kg·min],0.24,53281,DB00136,Calcitriol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],96,54314,DB00136,Calcitriol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],105,54315,DB00136,Calcitriol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],161,54316,DB00136,Calcitriol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],222,54317,DB00136,Calcitriol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[h·μg] / [dl],188,54318,DB00136,Calcitriol
,3392356,area under the curve (AUC),"Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[h·μg] / [dl],302,54319,DB00136,Calcitriol
,3392356,AUC,"Following Rocaltrol, serum calcium level increased (8.9 +/- .12 to 9.8 +/- .4 mg/dl, p less than 0.05), parathyroid hormone levels decreased (20.4 +/- 8.9 to 13.6 +/- 7.2 ng/ml, p less than 0.05), but there was no significant change in fasting plasma zinc, 2 hour plasma zinc, or AUC (89 +/- 3 micrograms/dl, 149 micrograms/dl, and 176 +/- 18 micrograms hr/dl, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[μg] / [dl],149,54320,DB00136,Calcitriol
,3392356,AUC,"Following Rocaltrol, serum calcium level increased (8.9 +/- .12 to 9.8 +/- .4 mg/dl, p less than 0.05), parathyroid hormone levels decreased (20.4 +/- 8.9 to 13.6 +/- 7.2 ng/ml, p less than 0.05), but there was no significant change in fasting plasma zinc, 2 hour plasma zinc, or AUC (89 +/- 3 micrograms/dl, 149 micrograms/dl, and 176 +/- 18 micrograms hr/dl, respectively).",Zinc tolerance test in uremia: effect of calcitriol supplementation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392356/),[h·μg] / [dl],176,54321,DB00136,Calcitriol
,24802860,t½,"After administration of rhPTH(1-84) 50 µg (n = 6) and 100 µg (n = 7), the approximate t½ was 2.5 to 3 hours.","Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24802860/),h,2.5 to 3,56560,DB00136,Calcitriol
,12031392,area under the concentration versus time curve,The mean total calcitriol exposure (area under the concentration versus time curve) in the prostate was 297.6 (+/-159) pg/hr/mL (intact) and 272.7 (+/-123.6) pg/hr/mL (castrated).,"Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12031392/),[pg] / [h·ml],297.6,62885,DB00136,Calcitriol
,12031392,area under the concentration versus time curve,The mean total calcitriol exposure (area under the concentration versus time curve) in the prostate was 297.6 (+/-159) pg/hr/mL (intact) and 272.7 (+/-123.6) pg/hr/mL (castrated).,"Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12031392/),[pg] / [h·ml],272.7,62886,DB00136,Calcitriol
,6897931,renal synthesis,Estimated renal synthesis ranged from 2-180 pmol/kg . day.,"Synthesis and metabolic clearance of 1,25-dihydroxyvitamin D as determinants of serum concentrations: a comparison of two methods. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6897931/),[pM] / [d·kg],2-180,66244,DB00136,Calcitriol
,11413535,peak calcitriol levels,"Doses of 0.48 microg/kg and above produced mean peak calcitriol levels of 1625 pg/mL, approximately 25-fold greater than top normal levels and well within the therapeutic range suggested by in vitro experiments.",A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413535/),[pg] / [ml],1625,73473,DB00136,Calcitriol
,3428866,elimination half life,"Dietary calcium deficiency resulted in a small increase of the 1,25(OH)2D3 elimination half life (P = 0.04) (normal diet: 16.3 +/- 1.8 hrs, n = 6; -Ca diet: 18.6 +/- 1.1 hrs, n = 5; -P diet: 16.0 +/- 1.4 hrs, n = 6; mean +/- SD).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,16.3,89128,DB00136,Calcitriol
,3428866,elimination half life,"Dietary calcium deficiency resulted in a small increase of the 1,25(OH)2D3 elimination half life (P = 0.04) (normal diet: 16.3 +/- 1.8 hrs, n = 6; -Ca diet: 18.6 +/- 1.1 hrs, n = 5; -P diet: 16.0 +/- 1.4 hrs, n = 6; mean +/- SD).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,18.6,89129,DB00136,Calcitriol
,3428866,elimination half life,"Dietary calcium deficiency resulted in a small increase of the 1,25(OH)2D3 elimination half life (P = 0.04) (normal diet: 16.3 +/- 1.8 hrs, n = 6; -Ca diet: 18.6 +/- 1.1 hrs, n = 5; -P diet: 16.0 +/- 1.4 hrs, n = 6; mean +/- SD).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,16.0,89130,DB00136,Calcitriol
,3428866,elimination half life,"The experiments with the vitamin D deficient rats showed a marked increase in the elimination half life of 1,25(OH)2D3 (36.4 +/- 6.8 hrs, n = 7), when compared to the rats on the normal diet (P = 0.001).","Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1,25-dihydroxyvitamin D3 in the rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428866/),h,36.4,89131,DB00136,Calcitriol
,21342321,PTH,The patients who achieved target PTH of 16-32 pmol/L were 82% in the calcitriol and 67% in the alfacalcidol group (P = 0.44).,Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342321/),[pM] / [l],16-32,94563,DB00136,Calcitriol
,3838330,Urinary calcium excretion (UCa),Urinary calcium excretion (UCa) was significantly increased from 199 +/- 19 mg/24 hr during the control period to similar levels of 302 +/- 26 mg/24 hr after 0.25 microgram twice a day and 284 +/- 31 mg/24 hr after 0.50 microgram daily.,Pharmacokinetics and biologic effects of calcitriol in normal humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],199,95280,DB00136,Calcitriol
,3838330,Urinary calcium excretion (UCa),Urinary calcium excretion (UCa) was significantly increased from 199 +/- 19 mg/24 hr during the control period to similar levels of 302 +/- 26 mg/24 hr after 0.25 microgram twice a day and 284 +/- 31 mg/24 hr after 0.50 microgram daily.,Pharmacokinetics and biologic effects of calcitriol in normal humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],302,95281,DB00136,Calcitriol
,3838330,Urinary calcium excretion (UCa),Urinary calcium excretion (UCa) was significantly increased from 199 +/- 19 mg/24 hr during the control period to similar levels of 302 +/- 26 mg/24 hr after 0.25 microgram twice a day and 284 +/- 31 mg/24 hr after 0.50 microgram daily.,Pharmacokinetics and biologic effects of calcitriol in normal humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],284,95282,DB00136,Calcitriol
,3838330,UCa,"With 0.50 microgram twice a day, UCa was 417 +/- 36 mg/24 hr, a value greater than after the lower doses (p less than 0.05).",Pharmacokinetics and biologic effects of calcitriol in normal humans. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3838330/),[mg] / [24·h],417,95283,DB00136,Calcitriol
,11037113,serum T(1/2),"4. In the male rat, the serum T(1/2) was 3 h, but in the female rat and minipig (both genders) T(1/2) = 8 h.",Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037113/),h,3,98053,DB00136,Calcitriol
,11037113,T(1/2),"4. In the male rat, the serum T(1/2) was 3 h, but in the female rat and minipig (both genders) T(1/2) = 8 h.",Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11037113/),h,8,98054,DB00136,Calcitriol
,29160302,effectiveness trough levels (Ctrough),"We explored the role of single-nucleotide polymorphisms (SNPs) involved in vitamin D metabolism, transport and activity on deferasirox pharmacokinetics and outcomes (effectiveness trough levels (Ctrough) and the area under the curve (AUC) cutoffs of 20 μg ml-1 and 360 μg ml-1 h-1, respectively; nonresponse AUC limit of 250 μg ml-1 h-1).","Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29160302/),[μg] / [ml],20,98087,DB00136,Calcitriol
,29160302,area under the curve (AUC),"We explored the role of single-nucleotide polymorphisms (SNPs) involved in vitamin D metabolism, transport and activity on deferasirox pharmacokinetics and outcomes (effectiveness trough levels (Ctrough) and the area under the curve (AUC) cutoffs of 20 μg ml-1 and 360 μg ml-1 h-1, respectively; nonresponse AUC limit of 250 μg ml-1 h-1).","Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29160302/),[μg] / [h·ml],360,98088,DB00136,Calcitriol
,29160302,nonresponse,"We explored the role of single-nucleotide polymorphisms (SNPs) involved in vitamin D metabolism, transport and activity on deferasirox pharmacokinetics and outcomes (effectiveness trough levels (Ctrough) and the area under the curve (AUC) cutoffs of 20 μg ml-1 and 360 μg ml-1 h-1, respectively; nonresponse AUC limit of 250 μg ml-1 h-1).","Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29160302/),[μg] / [h·ml],250,98089,DB00136,Calcitriol
,29160302,AUC limit,"We explored the role of single-nucleotide polymorphisms (SNPs) involved in vitamin D metabolism, transport and activity on deferasirox pharmacokinetics and outcomes (effectiveness trough levels (Ctrough) and the area under the curve (AUC) cutoffs of 20 μg ml-1 and 360 μg ml-1 h-1, respectively; nonresponse AUC limit of 250 μg ml-1 h-1).","Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29160302/),[μg] / [h·ml],250,98090,DB00136,Calcitriol
,8263137,t1/2,"Clearance of the peptide from the circulation followed an expontential pattern, with a mean t1/2 of 75 min.",Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263137/),min,75,101757,DB00136,Calcitriol
,23681426,peak (Umax),"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109602,DB00136,Calcitriol
,23681426,Uave,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109603,DB00136,Calcitriol
,23681426,urinary excretion rate,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],2.94,109604,DB00136,Calcitriol
,23681426,urinary excretion rate,"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),[μg] / [h],0.901,109605,DB00136,Calcitriol
,23681426,time to reach Umax (Tmax),"The peak (Umax) and the average (Uave) urinary excretion rate of alendronate and the time to reach Umax (Tmax) were 2.94 μg/h, 0.901 μg/h and 6.77 h, respectively.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),h,6.77,109606,DB00136,Calcitriol
,23681426,total cumulative urinary excretion,"The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),μg,21.6,109607,DB00136,Calcitriol
,23681426,total cumulative urinary excretion,"The total cumulative urinary excretion of alendronate (Ae₀₋₂₄ h) was 21.6 μg (0.432% of oral alendornate), which was similar to the reported values.",Improved dosage form of the combined alendronate and calcitriol (Maxmarvil®) on the absorption of alendronate in Korean postmenopausal women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23681426/),%,0.432,109608,DB00136,Calcitriol
,12506180,time to progression,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,11.4,111718,DB00136,Calcitriol
,12506180,survival,"Median time to progression was 11.4 months (95% CI, 8.7 to 14 months), and median survival was 19.5 months (95% CI, 15.3 months to incalculable).",Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506180/),month,19.5,111719,DB00136,Calcitriol
,19427587,AUC(0-infinity),"In subjects, AUC(0-infinity) and AUC(0-24h) were 267 and 246 pg h ml(-1), respectively.",Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[h·pg] / [ml],267,125239,DB00136,Calcitriol
,19427587,AUC(0-24h),"In subjects, AUC(0-infinity) and AUC(0-24h) were 267 and 246 pg h ml(-1), respectively.",Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[h·pg] / [ml],246,125240,DB00136,Calcitriol
,19427587,C(max),The C(max) of calcitriol was measured at 3.4h after administration as 50.0 pg ml(-1).,Pharmacokinetics of oral calcitriol in healthy human based on the analysis with an enzyme immunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19427587/),[pg] / [ml],50.0,125241,DB00136,Calcitriol
,3184598,Plasma concentration,"Plasma concentration of calcitonin was significantly higher in 16-week-old SHR (41.6 +/- 1.5 pg/ml) than in age-matched WKY (30.5 +/- 1.7, P less than 0.001).",Calcitriol synthesis is decreased in spontaneously hypertensive rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184598/),[pg] / [ml],41.6,126675,DB00136,Calcitriol
,3184598,Plasma concentration,"Plasma concentration of calcitonin was significantly higher in 16-week-old SHR (41.6 +/- 1.5 pg/ml) than in age-matched WKY (30.5 +/- 1.7, P less than 0.001).",Calcitriol synthesis is decreased in spontaneously hypertensive rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3184598/),,30.5,126676,DB00136,Calcitriol
,2161692,alpha (peak fractional absorption/h),"Gastrointestinal absorption of 45Ca, as represented by alpha (peak fractional absorption/h), increased from 0.397 +/- 0.173 to 0.552 +/- 0.210 (P less than 0.01) during hPTH 1-38 therapy and was moderately correlated with the increment in serum 1,25(OH)2D levels (r = 0.5, P less than 0.03).",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,0.397,132374,DB00136,Calcitriol
,2161692,alpha (peak fractional absorption/h),"Gastrointestinal absorption of 45Ca, as represented by alpha (peak fractional absorption/h), increased from 0.397 +/- 0.173 to 0.552 +/- 0.210 (P less than 0.01) during hPTH 1-38 therapy and was moderately correlated with the increment in serum 1,25(OH)2D levels (r = 0.5, P less than 0.03).",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,0.552,132375,DB00136,Calcitriol
,2161692,u,"Baseline fasting urinary excretion of OH-proline increased during hPTH 1-38 treatment from 30.5 +/- 13.9 mol/mmol creatinine to 43.4 +/- 17.5 immediately after hPTH 1-38 infusion (P less than 0.025), and mean excretion was persistently higher than baseline during intermittent treatment; the increased urine calcium and OH-proline excretion are consistent with PTH-induced activation of bone resorption.",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,30.5,132376,DB00136,Calcitriol
,2161692,u,"Baseline fasting urinary excretion of OH-proline increased during hPTH 1-38 treatment from 30.5 +/- 13.9 mol/mmol creatinine to 43.4 +/- 17.5 immediately after hPTH 1-38 infusion (P less than 0.025), and mean excretion was persistently higher than baseline during intermittent treatment; the increased urine calcium and OH-proline excretion are consistent with PTH-induced activation of bone resorption.",Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2161692/),,43.4,132377,DB00136,Calcitriol
,18246349,MTD,"The MTD was 3.75 microg/kg calcitriol in combination with cisplatin, and hypercalcemia was the dose-limiting toxicosis.",In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18246349/),[μg] / [kg],3.75,137018,DB00136,Calcitriol
>,18246349,Cmax,Calcitriol dosages >1.5 microg/kg achieved Cmax > or = 9.8 ng/mL and dosages >1.0 microg/kg achieved AUC > or = 45 h ng/mL.,In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18246349/),[ng] / [ml],9.8,137019,DB00136,Calcitriol
>,18246349,AUC,Calcitriol dosages >1.5 microg/kg achieved Cmax > or = 9.8 ng/mL and dosages >1.0 microg/kg achieved AUC > or = 45 h ng/mL.,In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18246349/),[h·ng] / [ml],45,137020,DB00136,Calcitriol
,7999841,maximal,The median maximal decrease was 51.4% of baseline (22.3%-74%).,"Single-dose oral calcitriol and changes of plasma 1,84iPTH in uremic children. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999841/),,51,141139,DB00136,Calcitriol
,10705507,specific radioactivity,"[22,23-(3)H4]1 alpha OHD3 (5) showed high specific radioactivity (111.5 Ci/mmol) and was used successfully in pharmacokinetics studies with rats.",Synthesis and pharmacokinetics of 1 alpha-hydroxyvitamin D3 tritiated at 22 and 23 positions showing high specific radioactivity. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10705507/),[ci] / [mM],111.5,141974,DB00136,Calcitriol
,23435876,RP2D,"The RP2D of 1,25-D3 was 60 mcg/m(2).",A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435876/),[mcg] / [m(2],60,143231,DB00136,Calcitriol
,23435876,time to progression,"Median time to progression was 5.8 months (95 % CI 3.4, 6.5), and median overall survival 8.7 months (95 % CI 7.6, 39.4).",A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435876/),month,5.8,143232,DB00136,Calcitriol
,23435876,overall survival,"Median time to progression was 5.8 months (95 % CI 3.4, 6.5), and median overall survival 8.7 months (95 % CI 7.6, 39.4).",A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23435876/),month,8.7,143233,DB00136,Calcitriol
,30299542,overall response rate,The overall response rate was 4%; the rate of disease control was 67% in patients who were pretreated with gemcitabine.,"A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299542/),%,4,152692,DB00136,Calcitriol
,30299542,Progression-free,"Progression-free and overall survival were 3.4 months and 6.5 months, respectively.","A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299542/),month,3.4,152693,DB00136,Calcitriol
,30299542,overall survival,"Progression-free and overall survival were 3.4 months and 6.5 months, respectively.","A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30299542/),month,6.5,152694,DB00136,Calcitriol
,10972662,AUC0-72h,"The peak serum level of 1,25(OH)2D3 and area under the curve baseline to 72 hours (AUC0-72h) were significantly higher after intravenous (IV) calcitriol (AUC0-72h oral, 1399 +/- 979 pg/mL. hour vs. IV 2793 +/- 1102 pg/mL. hour, P < 0.01), but the mean intestinal Sr absorption was not different [SrAUC0-240min during the 4 hours after Sr administration 2867 +/- 1101 FAD% (fraction of the absorbed dose) vs. 3117 +/- 1581 FAD% with oral and IV calcitriol, respectively].",No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972662/),[pg] / [h·ml],1399,154112,DB00136,Calcitriol
,10972662,AUC0-72h,"The peak serum level of 1,25(OH)2D3 and area under the curve baseline to 72 hours (AUC0-72h) were significantly higher after intravenous (IV) calcitriol (AUC0-72h oral, 1399 +/- 979 pg/mL. hour vs. IV 2793 +/- 1102 pg/mL. hour, P < 0.01), but the mean intestinal Sr absorption was not different [SrAUC0-240min during the 4 hours after Sr administration 2867 +/- 1101 FAD% (fraction of the absorbed dose) vs. 3117 +/- 1581 FAD% with oral and IV calcitriol, respectively].",No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972662/),[pg] / [h·ml],2793,154113,DB00136,Calcitriol
,33099115,flow rate,"Chromatographic separation was carried out on Kinetex C18 column (1.7 μm, 100 × 2.10 mm) under an isocratic elution at a flow rate of 0.4 mL/min with a total runtime of 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),[ml] / [min],0.4,158233,DB00136,Calcitriol
,33099115,total runtime,"Chromatographic separation was carried out on Kinetex C18 column (1.7 μm, 100 × 2.10 mm) under an isocratic elution at a flow rate of 0.4 mL/min with a total runtime of 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),min,3.5,158234,DB00136,Calcitriol
,33099115,total run time,"Additionally, only 20 μL of rat whole blood or plasma is required and the total run time per sample is 3.5 min.",Sensitive and rapid UHPLC-MS/MS assay for simultaneous quantifications of calcipotriol and paclitaxel in rat whole blood and plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33099115/),min,3.5,158235,DB00136,Calcitriol
,2382648,bioavailability,"The bioavailability of calcitriol, determined from the 24-hour area under the curve (AUC0-24) for the increase in serum calcitriol concentration above baseline values was 50% to 60% greater after IV, 2,340 +/- 523 pg.",Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382648/),%,50,159780,DB00136,Calcitriol
,2382648,bioavailability,"The bioavailability of calcitriol, determined from the 24-hour area under the curve (AUC0-24) for the increase in serum calcitriol concentration above baseline values was 50% to 60% greater after IV, 2,340 +/- 523 pg.",Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382648/),%,60,159781,DB00136,Calcitriol
,2382648,bioavailability,"The bioavailability of calcitriol, determined from the 24-hour area under the curve (AUC0-24) for the increase in serum calcitriol concentration above baseline values was 50% to 60% greater after IV, 2,340 +/- 523 pg.",Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382648/),pg,"2,340",159782,DB00136,Calcitriol
,30562554,terminal half-life,The terminal half-life of calcipotriol was approximately 1 h after an IV dose.,Pharmacokinetics of intra-articular vitamin D analogue calcipotriol in sheep and metabolism in human synovial and mesenchymal stromal cells. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562554/),h,1,159880,DB00136,Calcitriol
,30562554,systemic absorption,"After intra-articular dosing, the systemic absorption was between 1 and 13% during the observed 24 h.",Pharmacokinetics of intra-articular vitamin D analogue calcipotriol in sheep and metabolism in human synovial and mesenchymal stromal cells. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30562554/),%,1 and 13,159881,DB00136,Calcitriol
,16278401,C(max),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),[ng] / [ml],6.21,163154,DB00136,Calcitriol
,16278401,AUC(0-24),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),[h·ng] / [ml],41.3,163155,DB00136,Calcitriol
,16278401,AUC(0-infinity),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),,55.4,163156,DB00136,Calcitriol
,16278401,half-life (T(1/2)),"At the 165 microg dose, C(max) was 6.21 +/- 1.99 ng/mL, AUC(0-24) was 41.3 +/- 9.77 ng h/mL, AUC(0-infinity) was 55.4 +/- 8.44, and half-life (T(1/2)) was 16.2 hours.","Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16278401/),h,16.2,163157,DB00136,Calcitriol
,2991323,MCR,"In the 13 normal subjects, the MCR values were within a narrow range, with a mean +/- SD value of 37 +/- 6 ml/min, which, when combined with the mean steady state concentration of endogenous 1,25-(OH)2D (42 +/- 6 pg/ml), yielded a mean production rate of 2.2 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[ml] / [min],37,167504,DB00136,Calcitriol
,2991323,steady state concentration,"In the 13 normal subjects, the MCR values were within a narrow range, with a mean +/- SD value of 37 +/- 6 ml/min, which, when combined with the mean steady state concentration of endogenous 1,25-(OH)2D (42 +/- 6 pg/ml), yielded a mean production rate of 2.2 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[pg] / [ml],42,167505,DB00136,Calcitriol
,2991323,production rate,"In the 13 normal subjects, the MCR values were within a narrow range, with a mean +/- SD value of 37 +/- 6 ml/min, which, when combined with the mean steady state concentration of endogenous 1,25-(OH)2D (42 +/- 6 pg/ml), yielded a mean production rate of 2.2 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[μg] / [d],2.2,167506,DB00136,Calcitriol
,2991323,MCR,"In the 9 patients with absorptive hypercalciuria, MCR values also were tightly clustered, with a mean of 35 +/- 4 ml/min.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[ml] / [min],35,167507,DB00136,Calcitriol
,2991323,production rate,"However, the mean endogenous steady state 1,25-(OH)2D level was significantly elevated in these patients, such that the calculated mean 1,25-(OH)2D production rate was significantly elevated at 3.4 +/- 0.5 micrograms/day.","Elevated production rate of 1,25-dihydroxyvitamin D in patients with absorptive hypercalciuria. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2991323/),[μg] / [d],3.4,167508,DB00136,Calcitriol
,8076440,ka,"After i.v. administration A, ka, B, ke, t1/2, AUC24 and AUC0-->infinity were (mean +/- SD) 62.9 +/- 16.4 pg/ml, 0.76 +/- 0.30 h-1, 71.6 +/- 14.7 pg/ml, 0.017 +/- 0.015 h-1, 109.4 +/- 129.5 h, 1315.8 +/- 236.9 pg/ml x h and 10322.2 +/- 11473.7 pg/ml x h, respectively.","Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8076440/),[pg] / [ml],62.9,169579,DB00136,Calcitriol
,8076440,AUC0-->infinity,"After i.v. administration A, ka, B, ke, t1/2, AUC24 and AUC0-->infinity were (mean +/- SD) 62.9 +/- 16.4 pg/ml, 0.76 +/- 0.30 h-1, 71.6 +/- 14.7 pg/ml, 0.017 +/- 0.015 h-1, 109.4 +/- 129.5 h, 1315.8 +/- 236.9 pg/ml x h and 10322.2 +/- 11473.7 pg/ml x h, respectively.","Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8076440/),[pg] / [h·ml],10322.2,169580,DB00136,Calcitriol
,2004595,rate,"Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6-7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min).",On the mechanisms for the selective action of vitamin D analogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),[ml] / [min],48.2,170453,DB00136,Calcitriol
,2004595,rate,"Quantification of the metabolic clearance rate (MCR) of OCT in 8 normal dogs using a single bolus injection technique showed that OCT was cleared at a rate of 48.2 +/- 7.5 ml/min, approximately 6-7 times more rapidly than 1,25-(OH)2D3 (6.8 +/- 0.4 ml/min).",On the mechanisms for the selective action of vitamin D analogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),[ml] / [min],6.8,170454,DB00136,Calcitriol
,2004595,half-life,"The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3.",On the mechanisms for the selective action of vitamin D analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),h,2.5,170455,DB00136,Calcitriol
,2004595,half-life,"The estimated half-life of OCT in the circulation was 2.5 +/- 0.3 h compared to 7.0 +/- 0.6; n = 7 for 1,25-(OH)2D3.",On the mechanisms for the selective action of vitamin D analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),,7.0,170456,DB00136,Calcitriol
,2004595,MCR,Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4).,On the mechanisms for the selective action of vitamin D analogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),,56.8,170457,DB00136,Calcitriol
,2004595,t1/2,Uremia does not affect the rate of clearance of OCT from the circulation (MCR: 56.8 +/- 4.5; t1/2 = 2.1 +/- 0.2 n = 4).,On the mechanisms for the selective action of vitamin D analogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004595/),,2.1,170458,DB00136,Calcitriol
,12358640,terminal half-lives,"Calcitriol and paricalcitol have similar pharmacokinetic profiles, with terminal half-lives ranging from 5 to 10 hours in healthy subjects to 15-30 hours in patients undergoing dialysis.",Comparative review of the pharmacokinetics of vitamin D analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,5 to 10,175037,DB00136,Calcitriol
,12358640,terminal half-lives,"Calcitriol and paricalcitol have similar pharmacokinetic profiles, with terminal half-lives ranging from 5 to 10 hours in healthy subjects to 15-30 hours in patients undergoing dialysis.",Comparative review of the pharmacokinetics of vitamin D analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,15-30,175038,DB00136,Calcitriol
,12358640,half-life,"The half-life of 1alpha,25-(OH)2D2 is about 34 hours in healthy subjects and about 45 hours in dialysis patients, resembling physiologic blood concentrations of endogenous vitamin D.",Comparative review of the pharmacokinetics of vitamin D analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,34,175039,DB00136,Calcitriol
,12358640,half-life,"The half-life of 1alpha,25-(OH)2D2 is about 34 hours in healthy subjects and about 45 hours in dialysis patients, resembling physiologic blood concentrations of endogenous vitamin D.",Comparative review of the pharmacokinetics of vitamin D analogues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12358640/),h,45,175040,DB00136,Calcitriol
,9510866,Enteral absorption,"Enteral absorption of the ion (9.77 +/- 0.438 mmol.L-1.min, 240 min after Sr administration), expressed as the area under the plasma concentration-time curve (AUC), and renal clearance (CRE) in these subjects during the test (2.80 +/- 0.336 mL/min) were not different from values for 27 controls.",Strontium absorption and excretion in normocalciuric subjects: relation to calcium metabolism. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510866/),[mM·min] / [l],9.77,190120,DB00136,Calcitriol
,9510866,renal clearance (CRE),"Enteral absorption of the ion (9.77 +/- 0.438 mmol.L-1.min, 240 min after Sr administration), expressed as the area under the plasma concentration-time curve (AUC), and renal clearance (CRE) in these subjects during the test (2.80 +/- 0.336 mL/min) were not different from values for 27 controls.",Strontium absorption and excretion in normocalciuric subjects: relation to calcium metabolism. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9510866/),[ml] / [min],2.80,190121,DB00136,Calcitriol
,6753604,half-life,"24,25-Dihydroxyvitamin D3 is rapidly cleared from the plasma with a half-life of approximately 390 +/- 25 min (mean +/- SE).","Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6753604/),min,390,197496,DB00136,Calcitriol
,6753604,metabolic clearance rate,"The metabolic clearance rate of 24,25-dihydroxyvitamin D3 was 9.2 +/- 1.5 liters/day with a production rate of 26.4 +/- 7.2 micrograms/day (mean +/- SE).","Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6753604/),[l] / [d],9.2,197497,DB00136,Calcitriol
,6753604,production rate,"The metabolic clearance rate of 24,25-dihydroxyvitamin D3 was 9.2 +/- 1.5 liters/day with a production rate of 26.4 +/- 7.2 micrograms/day (mean +/- SE).","Physiology of 24,25-dihydroxyvitamin D3 in normal human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6753604/),[μg] / [d],26.4,197498,DB00136,Calcitriol
,7478149,plasma half-life,"In summary, the biological effects of 1,25(OH)2D3 on the parathyroid glands probably persist for several days, although the plasma half-life of 1,25(OH)2D3 is only several hours.",Optimum mode of administration of vitamin D in renal failure. Insights from experimental data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7478149/),h,several,197690,DB00136,Calcitriol
,6548386,t1/2,"Plasma pharmacokinetic studies in rats showed that (23S)-1,23,25-trihydroxy[3H]vitamin D3 was rapidly cleared from plasma (t1/2 = 60 min).","(23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1 alpha,25-dihydroxyvitamin D3 26,23-lactone biosynthesis. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6548386/),min,60,198092,DB00136,Calcitriol
,9252973,P excretion,"2.45 +/- 0.08 mmol/l) while urinary P excretion was increased (18.2 +/- 2.3 vs. 2.0 +/- 0.3 mmol/4 days), together with a decrease in plasma calcitriol concentration (54.4 +/- 2.6 vs. 79.6 +/- 2.5 ng/l), but no change of the circulating parathyroid hormone level.",Stimulation by citric acid of calcium and phosphorus bioavailability in rats fed a calcium-rich diet. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252973/),[mM] / [4·d],18.2,202787,DB00136,Calcitriol
,9252973,P excretion,"2.45 +/- 0.08 mmol/l) while urinary P excretion was increased (18.2 +/- 2.3 vs. 2.0 +/- 0.3 mmol/4 days), together with a decrease in plasma calcitriol concentration (54.4 +/- 2.6 vs. 79.6 +/- 2.5 ng/l), but no change of the circulating parathyroid hormone level.",Stimulation by citric acid of calcium and phosphorus bioavailability in rats fed a calcium-rich diet. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252973/),[mM] / [4·d],2.0,202788,DB00136,Calcitriol
,25098404,total chromatographic run time,The total chromatographic run time was 6.0 min and the elution of PAR and PAR-d6 occurred at ~2.6 min.,Sensitive method for the determination of paricalcitol by liquid chromatography and mass spectrometry and its application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25098404/),min,6.0,211872,DB00136,Calcitriol
,2831435,plasma half-life,10-Keto-D3 exhibited a plasma half-life of only 6 min.,The biological assessment of vitamin D3 metabolites produced by rumen bacteria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2831435/),min,6,216942,DB00136,Calcitriol
,19396601,peak serum calcitriol concentration (C (max)),Mean (+/-SE) peak serum calcitriol concentration (C (max)) at the MTD (125 microg/week calcitriol) was 11.17 +/- 2.62 ng/ml and the systemic exposure (AUC(0-72 h)) of 53.30 +/- 10.49 ng h/ml.,A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396601/),[ng] / [ml],11.17,222257,DB00136,Calcitriol
,19396601,AUC(0-72 h)),Mean (+/-SE) peak serum calcitriol concentration (C (max)) at the MTD (125 microg/week calcitriol) was 11.17 +/- 2.62 ng/ml and the systemic exposure (AUC(0-72 h)) of 53.30 +/- 10.49 ng h/ml.,A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19396601/),[h·ng] / [ml],53.30,222258,DB00136,Calcitriol
,9623560,time: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),weeks,14.2,225118,DB00136,Calcitriol
,9623560,time: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),weeks,12.2,225119,DB00136,Calcitriol
,9623560,rate: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),[%·pth] / [week],7.4,225120,DB00136,Calcitriol
,9623560,rate: pulse,"The time required for the PTH to decrease to 100 pg/ml and the rate of decline in PTH were similar (time: pulse = 14.2 +/- 6.8 weeks, daily = 12.2 +/- 7 weeks; rate: pulse = 7.4 +/- 4.2 vs daily = 8.4 +/- 4.2% PTH/week; P = NS).",Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623560/),[%·pth] / [week],8.4,225121,DB00136,Calcitriol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,33,225556,DB00136,Calcitriol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,19,225557,DB00136,Calcitriol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,73,225558,DB00136,Calcitriol
,9124548,bioavailability (true absorption),"The mean bioavailability (true absorption) was 33% for calcium and 19% for strontium (ratio 1.7:1), whereas, after 1,25(OH)2D(3) pretreatment, it was 73 and 43% (ratio 1.7:1), respectively.",Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9124548/),%,43,225559,DB00136,Calcitriol
,17066293,MTD,The MTD for weekly DN-101 was established as 45 mug.,"Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17066293/),μg,45,232515,DB00136,Calcitriol
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],47.4,241630,DB00136,Calcitriol
,12969965,clearance,"On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54.",Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12969965/),[ml] / [m2·min],29.2,241631,DB00136,Calcitriol
,2347542,MCR,The MCR averaged 0.201 +/- 0.003 ml.min-1.kg-1 in fed male rats weighing 200-300 g.,"Production and metabolic clearance rates of 1,25-dihydroxyvitamin D3 during maturation in rats: studies using a rapid, primed-infusion technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2347542/),[ml] / [kg·min],0.201,249811,DB00136,Calcitriol
,3753709,PR,"With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38 +/- 3 to 68 +/- 6 pg/ml, P less than 0.001; the PR increased from 1.8 +/- 0.2 to 3.8 +/- 0.6 micrograms/d, P less than 0.005; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,1,260591,DB00136,Calcitriol
,3753709,PR,"With phosphorus restriction, the serum concentration of 1,25-(OH)2D increased by 80% from a mean of 38 +/- 3 to 68 +/- 6 pg/ml, P less than 0.001; the PR increased from 1.8 +/- 0.2 to 3.8 +/- 0.6 micrograms/d, P less than 0.005; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,3,260592,DB00136,Calcitriol
,3753709,PR,"The PR decreased to 1.3 +/- 0.2 micrograms/d, P less than 0.05; the MCR did not change significantly.","Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3753709/),,1,260593,DB00136,Calcitriol
,26642947,plasma Ctrough,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],73,269342,DB00136,Calcitriol
,26642947,plasma Ctrough,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],247,269343,DB00136,Calcitriol
,26642947,intracellular,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],"16,863",269344,DB00136,Calcitriol
,26642947,Ctrough,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],"16,863",269345,DB00136,Calcitriol
,26642947,Ctrough,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],"13,535",269346,DB00136,Calcitriol
,26642947,plasma Cmax,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],5627,269347,DB00136,Calcitriol
,26642947,plasma Cmax,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],2229,269348,DB00136,Calcitriol
,26642947,intracellular,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],"133,830",269349,DB00136,Calcitriol
,26642947,Cmax,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],"133,830",269350,DB00136,Calcitriol
,26642947,Cmax,"Considering weeks 2 and 4, median plasma Ctrough were 73 ng/mL and 247 ng/mL, intracellular Ctrough were 16,863 ng/mL and 13,535 ng/mL, plasma Cmax were 5627 ng/mL and 2229 ng/mL, intracellular Cmax were 133,830 ng/mL and 78,544 ng/mL.",Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26642947/),[ng] / [ml],"78,544",269351,DB00136,Calcitriol
,3623424,FACa,"In the basal state, the radiocalcium transit was significantly decreased (P less than 0.02) at 15 min in patients treated with prednisolone, but FACa at 6 h was not significantly decreased (51 +/- 5 vs. 60 +/- 5% TD).",Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623424/),%,51,272503,DB00136,Calcitriol
,3623424,FACa,"In the basal state, the radiocalcium transit was significantly decreased (P less than 0.02) at 15 min in patients treated with prednisolone, but FACa at 6 h was not significantly decreased (51 +/- 5 vs. 60 +/- 5% TD).",Calcium absorption in corticoid treated subjects effects of a single oral dose of calcitriol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623424/),%,60,272504,DB00136,Calcitriol
